Patient consent was waived by the Ethics Committee due to the retrospective nature of this study. The purpose of this retrospective study was to summarize the clinical characteristics and evaluate the management approaches of primary breast DLBCL in the era of rituximab.Īfter obtaining approval from the Independent Ethics Committee of Zhejiang Cancer Hospital, the patients with newly diagnosed NHL (n=1,281) treated between April 2006 and May 2013 in our center were reviewed and the patients with primary breast DLBCL were retrospectively evaluated. 10 The complete response rate, event free-survival, and OS were similar to those of historical controls.
#RITXUMIAB RADIATION UNFOLDER TRIAL TRIAL#
The second was a single-arm trial utilizing a dose-dense regimen (CEOP-14) and rituximab in 32 patients. 8 The results of the first trial indicated that chemotherapy combined with radiation therapy was the best treatment with improvement in event-free survival and overall survival (OS). The first trial included 96 patients who were randomized to chemotherapy, radiation therapy, or both in the prerituximab era. Optimal treatment strategies for primary breast DLBCL have remained undefined to date, only two prospective trials have been reported. Additionally, a tendency for central nervous system (CNS) progression and a significant risk of contralateral breast involvement have been identified. 1 It represents ~1% of all non-Hodgkin lymphoma (NHL), and the most predominant subtype is diffuse large B-cell lymphoma (DLBCL). Primary breast lymphoma (PBL) was first described in 1959. Keywords: primary breast lymphoma, diffuse large B-cell lymphoma, rituximab, prognosis Further prospective studies are needed to evaluate the role of rituximab for primary breast DLBCL. Adding rituximab might improve survival in patients with primary breast DLBCL.
A nonstatistically significant increase in PFS and overall survival was observed when rituximab was administered (5-year PFS: 90% vs 71.4%, P=0.285 5-year overall survival: 90% vs 71.4%, P=0.239).Ĭonclusion: Primary breast DLBCL appears to be a rare disease. The estimated 5-year overall survival and progression-free survival (PFS) rates of all the patients were 78.9% and 79.2%, respectively. All patients had the disease detected with a palpable mass. Results: For the whole group, the median age was 50 years (range 24–69 years). Patients and methods: A total of 24 female patients with newly diagnosed primary breast DLBCL treated between April 2006 and May 2013 were analyzed retrospectively. *These authors contributed equally to this workīackground and objective: The aim of this study was to summarize the clinical characteristics and evaluate the management approaches of primary breast diffuse large B-cell lymphoma (DLBCL) in the era of rituximab. Na Zhang,* Caineng Cao,* Yuan Zhu, Peng Liu, Luying Liu, Ke Lu, Jialin Luo, Ning Zhouĭepartment of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China
0 kommentar(er)
